DDInter1491 DDInter1147
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Pomalidomide {u} (Compound) binds {v} (Gene) TNF
Pomalidomide {u} (Compound) causes {v} (Side Effect) Dermatitis
Pomalidomide (Compound) resembles Lenalidomide (Compound)
Pomalidomide (Compound) binds TNF (Gene)
Pomalidomide (Compound) causes Dermatitis (Side Effect)